← Back to Search

F-Tryptophan PET/CT Imaging for Cancer

Phase 1
Recruiting
Led By Csaba Juhasz, M.D.,Ph.D
Research Sponsored by Barbara Ann Karmanos Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during procedure (from right after tracer injection to 1-hour post-injection)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new imaging procedure that may help doctors better assess a patient's response to cancer treatment and plan future treatment.

Who is the study for?
Adults over 18 with certain cancers (brain, breast, neuroendocrine, colorectal) and visible tumors at least 1cm in diameter. Participants must be able to undergo a PET/CT scan for 70 minutes and not be pregnant or breastfeeding. They should have an ECOG performance status of ≤2 and meet specific criteria based on their cancer type.
What is being tested?
The trial is testing the effectiveness of a new imaging procedure using F-Tryptophan PET/CT to distinguish between tumor tissue and non-tumor tissue in various cancers. The goal is to improve treatment planning by better identifying how tumors take up Tryptophan.
What are the potential side effects?
As this trial focuses on an imaging technique rather than a drug intervention, side effects are minimal but may include discomfort from lying still during the scan or reactions related to contrast agents if used.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during procedure (from right after tracer injection to 1-hour post-injection)
This trial's timeline: 3 weeks for screening, Varies for treatment, and during procedure (from right after tracer injection to 1-hour post-injection) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Breast
The percent difference in tracer uptake values between the tumor mass and the background (non-tumor tissue)
Secondary study objectives
Overall radiation dose to the study participants.
Radiation doses to the various organs.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]FETrp PET radiotracerExperimental Treatment1 Intervention
All participants will receive the tracer to evaluate the uptake of \[18F\]FETrp PET/CT on intra- and extracranial cancers.

Find a Location

Who is running the clinical trial?

Barbara Ann Karmanos Cancer InstituteLead Sponsor
164 Previous Clinical Trials
9,224 Total Patients Enrolled
1 Trials studying Neuroendocrine Tumors
6 Patients Enrolled for Neuroendocrine Tumors
Washington University School of MedicineOTHER
1,991 Previous Clinical Trials
2,295,836 Total Patients Enrolled
3 Trials studying Neuroendocrine Tumors
111 Patients Enrolled for Neuroendocrine Tumors
Csaba Juhasz, M.D.,Ph.DPrincipal InvestigatorBarbara Ann Karmanos Cancer Institute

Media Library

[18F]FETrp PET radiotracer Clinical Trial Eligibility Overview. Trial Name: NCT05556473 — Phase 1
Neuroendocrine Tumors Research Study Groups: [18F]FETrp PET radiotracer
Neuroendocrine Tumors Clinical Trial 2023: [18F]FETrp PET radiotracer Highlights & Side Effects. Trial Name: NCT05556473 — Phase 1
[18F]FETrp PET radiotracer 2023 Treatment Timeline for Medical Study. Trial Name: NCT05556473 — Phase 1
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top